Hamostaseologie 2006; 26(S 01): S55-S52
DOI: 10.1055/s-0037-1616990
Original Article
Schattauer GmbH

Gerinnungsmanagement bei Polytrauma

Coagulation management in major trauma
H. Schöchl
1   Abteilung für Anästhesiologie und Intensivmedizin, AUVA-Unfallkrankenhaus Salzburg, Österreich
› Author Affiliations
Further Information

Publication History

Publication Date:
27 December 2017 (online)

Zusammenfassung

Bei der Therapie traumabedingter Koagulopathien sind zunächst die Hypothermie und Azidose aggressiv zu behandeln. Bereits im Schockraum ist bei polytraumatisierten Patienten häufig ein Fibrinogenmangel nachweisbar, daneben führen infundierte Kolloide zusätzlich zu Fibrinpolymerisationsstörungen. Der frühe Einsatz von Fibrinogen scheint deshalb gerechtfertigt. Mit PPSB und/oder Frischplasma können depletierte Gerinnungsfaktoren substituiert werden, angesichts des Infektionsrisikos ist bei der Gabe von Thrombozytenkonzentraten Zurückhaltung angezeigt. Das Potenzial hämostatischer Medikamente (z. B. Antifibrinolytika und DDAVP) ist für diese Indikation nur durch wenige Studien belegt, kann im Einzelfall allerdings sehr hilfreich sein. Die Gabe von rekombinantem FVIIa erreichte in einer randomisierten, kontrollierten Studie keine nachhaltige Verbesserung des Outcomes von Traumapatienten. Gleichzeitiges Anheben der Gerinnungsinhibitoren (Antithrombin) wird diskutiert, erscheint aber in der akuten Phase einer lebensbedrohlichen Blutung nicht sinnvoll.

Summary

In trauma associated coagulopathy, the initial treatment consists of hypothermia and acidosis have to be treated aggressively. Already in in the emergency room, fibrinogen deficiency can be detected frequently, in addition, colloids interfere with fibrin polymerisation. Under these aspects, the early administration of fibrinogen seems to be justified. Depleted coagulation factors can be substituted with PPSB and/or fresh frozen plasma, while in view of a risk of infection, retaining administration of platelet concentrates is indicated. The potential of using haemostatic agents like antifibrinolytics and DDAVP for this indication is only supported by few studies, although in individual cases it may be very helpful. The administration of recombinant FVIIa could not achieve sustainable amelioration of the outcome of trauma patients in a randomised controlled trial. Raising inhibitors of coagulation (antithrombin) simultaneously to antihaemorragic therapy is being discussed, but seems not reasonable in the acute phase of a life-threatening haemorrage.

 
  • Literatur

  • 1 Armand R, Hess JR. Treating coagulopathy in trauma patients. Transfus Med Rev 2003; 17: 223-31.
  • 2 Barletta JF, Ahrens CL, Tyburski JG. et al. A review of recombinant Factor VIIa for refractory bleeding in nonhemophilic trauma Patients. J Trauma 2005; 58: 646-51.
  • 3 Bellamy RF. Combat trauma overview. In: Zajtchuk R, Bellamy RF, Grande CM. (eds). Anaesthesia and perioperative care of the combat casualty: Textbook of military medicine. Falls church, VA: Office of the surgeon General; 1995: 1-42.
  • 4 Boffard KD, Riou B, Warren B. et al. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. J Trauma 2005; 59: 8-15.
  • 5 Brohi K, Singh J, Heron M. et al. Acute traumatic coagulopathy. J Trauma 2003; 54: 1127-30.
  • 6 Cosgriff N, Moore EE, Sauaia A. et al. Predicting life-threatening coagulopathy in the massively transfused trauma patient: hypothermia and acidoses revisited. J Trauma 1997; 42: 857-61.
  • 7 Dutton RP, Mackenzie CF, Scalea TM. Hypotensive resuscitation during active hemorrhage: impact on in-hospital mortality. J Trauma 2002; 52: 1141-6.
  • 8 Dzik WH. Predicting hemorrhage using preoperative coagulation screening assays. Curr Hematol Rep (United States) 2004; 3: 324-30.
  • 9 Enderson BL, Chen JP, Robinson R. et al. Fibrinolysis in multisystem trauma patients. J Trauma 1991; 31: 1240-6.
  • 10 Fries D, Innerhofer P, Schobersberger W. Coagulation management in trauma patients. Curr Opin Anaesthesiol 2002; 15: 217-23.
  • 11 Gofrit ON, Leibovici D, Shapira SC. The trimodal death distribution of trauma victims: military experience from the Lebanon war. Mil Med 1997; 162: 24-6.
  • 12 Goodnight SH, Kenoyer G, Rapaport SI. et al. Defibrination after brain-tissue destruction: A serious complication of head injury. N Engl J Med 1974; 290: 1043-7.
  • 13 Hardy JF, Moerloose P, Samama M. Massive transfusion and coagulopathy: pathophysiology and implications for clinical management. Can J Anesth 2004; 51: 293-310.
  • 14 Hiippala ST, Myllyla GJ, Vahtera EM. Hemostatic factors and replacement of major blood loss with plasma-poor red cell concentrates. Anesth Analg 1995; 81: 360-5.
  • 15 Hiippala S. Replacement of massive blood loss. Vox Sang 1998; 74 (Suppl. 02) p 399-407.
  • 16 Johnson JW, Gracias VH, Schwab CW. et al. Evolution in damage control for exsanguinating penetrating abdominal injury. J Trauma 2001; 51: 261-9.
  • 17 Jurkovich GJ, Greiser WB, Lutermann A. et al. Hypothermia in trauma victims: an omnious predictor of survival. J Trauma 1987; 27: 1019-24.
  • 18 Kaufmann CR, Dwyer KM, Crews JD. et al. Usefulness of thrombelastography in assessment of trauma patient coagulation. J Trauma 1997; 42: 716-20.
  • 19 Lampl L, Seifried E, Tisch M. et al. Hemostatic disorders following polytrauma – the role of physiologic coagulation inhibitors during the preclinical phase. Anasthesiol Intensivmed Notfallmed Schmerzther 1992; 27: 31-6.
  • 20 Levi M. Pro-hemostatic therapy for prevention and treatment of bleeding. In: Vincant JL. (ed). Yearbook of Intensive Care and Emerg Medicine 2002. Heidelberg: Springer; 2002
  • 21 Martini WZ, Pusateri AE, Uscilowicz JM. et al. Independent contributions of hypothermia and acidosis to coagulopathy in swine. J Trauma 2005; 58: 1002-9.
  • 22 Meng ZH, Wolberg AS, Monroe DM. et al. The effect of temperature and pH on the activity of factor VIIa: implications for the efficacy of high-dose factor VIIa in hypothermic and acidotic patients. J Trauma 2003; 55: 886-91.
  • 23 Sauaia A, Moore FA, Moore EE. et al. Epidemiology of trauma death: a reassessment. J Trauma 1995; 38: 185-93.
  • 24 Scope A, Farkash U, Lynn M. et al. Mortality epidemiology in low-intensity warfare: Israel Defense Forces experience. Injury 2001; 32: 1-3.
  • 25 Rohrer MJ, Natale AM. Effect of hypothermia on the coagulation cascade. Crit Care Med 1992; 20: 1402-5.
  • 26 Valeri CR, Cassidy G, Pivacek LE. et al. Anemiainduced increase in the bleeding time: implications for treatment of nonsurgical blood loss. Transfusion 2001; 41: 977-83.
  • 27 Wilson RF, Dulchavsky SA, Soullier G. et al. Problems with 20 or more blood transfusions in 24 hours. Am Surg 1987; 53: 410-7.
  • 28 Wolberg AS, Meng ZH, Monroe DM. et al. A systematic evaluation of the effect of temperature on coagulation enzyme activity and platelet function. J Trauma 2004; 56: 1221-8.
  • 29 Waydhas C, Nast-Kolb D, Gippner-Steppert C. et al. High-dose antithrombin III treatment of severely injured patients: results of a prospective study. J Trauma 1998; 45: 931-40.